Business Context and Reporting Period
This Form 8-K filing by InMed Pharmaceuticals Inc. reports on the Annual General Meeting of Shareholders held on December 15, 2022. The company is incorporated in British Columbia, Canada, and its common shares trade on The Nasdaq Stock Market LLC under the symbol INM. The registrant is classified as an emerging growth company.
Key Financial Metrics
This filing is a current report regarding corporate governance events and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
Shareholders voted in favor of all items of business presented at the meeting:
- Proposal 1: Election of Directors
- Eric A. Adams: 94.90% For (159,223 votes)
- Andrew Hull: 94.34% For (158,282 votes)
- Janet Grove: 96.70% For (162,246 votes)
- Bryan Baldasare: 95.82% For (160,764 votes)
- Nicole Lemerond: 96.66% For (162,174 votes)
All nominees received 179,813 broker non-votes.
- Proposal 2: Appointment of Independent Registered Public Accounting Firm
- Shareholders approved the appointment of Marcum LLP to serve until the 2023 Annual General Meeting.
- Votes For: 339,548 (97.68%)
- Votes Against: 0 (0%)
- Abstain: 8,047
Guidance, Outlook, and Risks
The filing includes a Regulation FD disclosure referencing a press release (Exhibit 99.1) announcing the voting results. No specific financial guidance, management commentary on future outlook, or discussion of material risks and contingencies is contained within the text of this Form 8-K.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for any additional commentary on the voting results.
- Review the company's most recent 10-K or 10-Q filings for financial performance data, as this 8-K contains no financial metrics.
- Confirm the tenure of the newly elected directors, which extends until the 2023 Annual General Meeting.
- Monitor future filings for the engagement letter or audit report from the newly appointed auditor, Marcum LLP.